Ireland’s Horizon Therapeutics became the first to win regulatory approval in the United States for the treatment of Thyroid Eye Disease (TED), a progressive autoimmune disorder that can threaten the vision of those afflicted.
https://www.pharmalive.com/wp-content/uploads/2020/01/Tepezza-Horizon-Approval-1-22-20.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2020-01-22 12:14:532020-01-23 13:49:39Horizon Therapeutics Wins FDA Approval for First Thyroid Eye Disease Treatment